Lightview Capital, a notable lower middle market private equity firm, has successfully executed the sale of Array, a prominent content engagement partner for life sciences events, to WCG, a global leader in clinical research solutions. This transaction not only signifies a pivotal development in the clinical research sector but also underscores a strategic alignment between Array’s advanced technology and WCG’s extensive research capabilities.

Founded in 2003, Array has emerged as a leader in the life sciences sector by offering a distinctive combination of data-driven technology and engagement services. These services are renowned for their ability to enhance business results and generate actionable insights. Since being acquired by Lightview Capital in 2019, Array has experienced substantial growth. The private equity firm’s investment enabled Array to refine its proprietary technology, broaden its meeting delivery capabilities to include virtual and hybrid formats, and fortify its reputation as a reliable technology partner in the life sciences industry.

Marc Crawford, Chief Executive Officer of Array, commented on the transformative impact of Lightview’s support. Crawford highlighted that the partnership was instrumental in Array’s growth and expressed excitement about joining WCG. He emphasised that the acquisition will continue Array’s mission of advancing clinical research and improving lives through innovative solutions.

Conor Mullett, Managing Director at Lightview Capital, praised the successful sale, describing it as a significant milestone for both Array and Lightview. Mullett noted that the transaction reflects Lightview’s ability to build and scale market-leading platforms within the business services and tech-enabled services sectors. This sale not only demonstrates the successful growth strategy of Lightview but also the scalability and strategic value of Array’s technology in the clinical research landscape.

Union Square Advisors and Madison Park Group served as co-lead financial advisors, providing essential guidance throughout the transaction. DLA Piper acted as the legal advisor to Lightview and Array, ensuring a smooth and compliant process. Array’s extensive experience—spanning over 20 years and more than 10,000 events—reinforces its expertise in the sector. The company’s innovative integration of technology and services has consistently engaged over 90% of audience members, enhanced knowledge transfer, and delivered actionable analytics. These capabilities are expected to align well with WCG’s goals in advancing clinical research.

The sale comes at a time when the clinical research sector is experiencing rapid growth and transformation. With the increasing emphasis on data-driven insights and virtual solutions, Array’s technological advancements and engagement strategies are poised to complement WCG’s extensive research operations. This strategic acquisition is anticipated to drive further innovation and efficiency in clinical trials, ultimately benefiting the broader healthcare industry.

Key Points in Array’s Sale to WCG

1. Strategic Sale: Lightview Capital’s sale of Array to WCG enhances clinical research solutions, reflecting a strategic industry alignment.
2. Array’s Growth: Under Lightview’s ownership, Array has expanded its technology and delivery capabilities, positioning itself as a leading player in life sciences.
3. Industry Impact: The transaction highlights the synergy between Array’s engagement technology and WCG’s research expertise, promising advancements in clinical trials.

Expert Opinions

Marc Crawford, CEO of Array, praised Lightview’s support, noting its crucial role in Array’s growth. Crawford expressed enthusiasm about the merger with WCG, which is expected to further Array’s mission in clinical research.

Conor Mullett, Managing Director at Lightview Capital, recognised the transaction as a testament to Lightview’s capability to scale successful platforms and build market-leading entities in the business services and tech-enabled sectors.

  Array, business services, clinical research, DLA Piper, life sciences events, Lightview Capital, Madison Park Group, Technology, Union Square Advisors, WCG